Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-2.08%
1,043.99
-22.22
-2.08%
—1,066.211,064.941,064.941,038.97——
SIXC
Communications
SIXC
Communications
SIXC
-0.12%
610.41
-0.75
-0.12%
—611.16611.16612.25607.39——
SIXE
Energy
SIXE
Energy
SIXE
+0.19%
1,272.39
+2.46
+0.19%
—1,269.931,273.161,275.781,262.69——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.19%
1,699.91
-20.50
-1.19%
—1,720.411,717.391,717.391,696.26——
SIXM
Financials
SIXM
Financials
SIXM
-0.01%
637.08
-0.050
-0.01%
—637.13637.40637.74631.77——
SIXR
Staples
SIXR
Staples
SIXR
+0.69%
872.19
+5.94
+0.69%
—866.25865.77873.10858.72——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.31%
215.31
+0.67
+0.31%
—214.64214.64215.56213.49——
SIXT
Technology
SIXT
Technology
SIXT
-1.99%
3,441.14
-69.99
-1.99%
—3,511.133,481.073,527.593,441.31——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
888.36
+1.44
+0.16%
—886.92885.23889.14881.74——
SIXV
Health care
SIXV
Health care
SIXV
+1.18%
1,487.88
+17.39
+1.18%
—1,470.491,470.681,489.741,462.16——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.47%
2,315.21
-34.56
-1.47%
—2,349.772,332.172,332.172,310.68——
MOLN:NASDAQ
Molecular Partners AG
$3.80
0.00%
(0.00) 1D
May 18, 9:38:57 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MOLN...
Mkt. cap
149.84M
Avg. vol.
3.71K
Volume
1.04K
52-wk high
$5.36
52-wk low
$3.41
EPS
-$2.00
Beta
1.01
Shares outstanding
40.38M
No. of employees
134
News stories
From sources across the web
Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
About Molecular Partners AG
CEO-
Employees134
Founded2004
Headquarters-
SectorBiotechnology
Websitemolecularpartners.com
Last report
May 27, 2026
Fiscal Period
Q1 2026
EPS / Est. (CHF)
-CHF 0.35 / -CHF 0.33
-6.06%miss
Revenue / Est. (CHF)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
10.71M
8.33M
8.18M
-
Cost of revenue
10.71M
8.33M
8.18M
-
Research and development expenses
-
-
-
9.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.99M
3.60M
4.48M
4.00M
Operating expense
3.99M
3.60M
4.48M
13.44M
Total operating expenses
14.70M
11.93M
12.67M
13.44M
Operating income
-14.70M
-11.93M
-12.67M
-13.44M
Other non operating income
-3.00K
-2.00K
-5.00K
310.00K
EBT including unusual items
-20.40M
-11.84M
-12.64M
-13.14M
EBT excluding unusual items
-17.78M
-11.72M
-12.69M
-13.14M
Income tax expense
-
-
4.00K
-
Effective tax rate
-
-
-0.03%
-
Other operating expenses
-
-
-
-
Net income
-20.40M
-11.84M
-12.65M
-13.14M
Net profit margin
-
-
-
-
Earnings per share
-0.56
-0.33
-0.36
-0.35
Interest and investment income
420.00K
366.00K
234.00K
-
Interest expense
-4.00K
-3.00K
-6.00K
-11.00K
Net interest expenses
416.00K
363.00K
228.00K
-11.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.15M
-11.40M
-12.44M
-12.94M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer